🚀 VC round data is live in beta, check it out!
Iterum Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Iterum Therapeutics and similar public comparables like Respiratorius, PharmaLundensis, Reboost Blockchain, Aptahem and more.
Iterum Therapeutics Overview
About Iterum Therapeutics
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Founded
2015
HQ
Employees
9
Website
Sectors
Financials (LTM)
EV
$24M
Iterum Therapeutics Financials
Iterum Therapeutics reported last 12-month revenue of $3M and negative EBITDA of ($22M).
In the same LTM period, Iterum Therapeutics generated $3M in gross profit, ($22M) in EBITDA losses, and had net loss of ($25M).
Revenue (LTM)
Iterum Therapeutics P&L
In the most recent fiscal year, Iterum Therapeutics reported revenue of — and EBITDA of ($22M).
Iterum Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | ($254K) | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($22M) | XXX | ($22M) | XXX | XXX | XXX |
| EBITDA Margin | (643%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (643%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($25M) | XXX | ($25M) | XXX | XXX | XXX |
| Net Margin | (729%) | XXX | — | XXX | XXX | XXX |
| Net Debt | — | — | $21M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Iterum Therapeutics Stock Performance
Iterum Therapeutics has current market cap of $1M, and enterprise value of $24M.
Market Cap Evolution
Iterum Therapeutics' stock price is $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24M | $1M | 15.7% | XXX | XXX | XXX | $-0.46 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIterum Therapeutics Valuation Multiples
Iterum Therapeutics trades at 6.9x EV/Revenue multiple, and (1.1x) EV/EBITDA.
EV / Revenue (LTM)
Iterum Therapeutics Financial Valuation Multiples
As of April 17, 2026, Iterum Therapeutics has market cap of $1M and EV of $24M.
Equity research analysts estimate Iterum Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Iterum Therapeutics has a P/E ratio of (0.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (1.1x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 8.5x | XXX | (94.7x) | XXX | XXX | XXX |
| P/E | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Iterum Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Iterum Therapeutics Margins & Growth Rates
Iterum Therapeutics' revenue in the last 12 month grew by 602%.
Iterum Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.0M for the same period.
Iterum Therapeutics' rule of 40 is 988% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Iterum Therapeutics' rule of X is 2713% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Iterum Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 602% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (643%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (82%) | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 988% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 2713% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 582% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 124% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Iterum Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Iterum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Respiratorius | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaLundensis | XXX | XXX | XXX | XXX | XXX | XXX |
| Reboost Blockchain | XXX | XXX | XXX | XXX | XXX | XXX |
| Aptahem | XXX | XXX | XXX | XXX | XXX | XXX |
| Clearside Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Iterum Therapeutics M&A Activity
Iterum Therapeutics acquired XXX companies to date.
Last acquisition by Iterum Therapeutics was on XXXXXXXX, XXXXX. Iterum Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Iterum Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIterum Therapeutics Investment Activity
Iterum Therapeutics invested in XXX companies to date.
Iterum Therapeutics made its latest investment on XXXXXXXX, XXXXX. Iterum Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Iterum Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Iterum Therapeutics
| When was Iterum Therapeutics founded? | Iterum Therapeutics was founded in 2015. |
| Where is Iterum Therapeutics headquartered? | Iterum Therapeutics is headquartered in Ireland. |
| How many employees does Iterum Therapeutics have? | As of today, Iterum Therapeutics has over 9 employees. |
| Who is the CEO of Iterum Therapeutics? | Iterum Therapeutics' CEO is Corey N. Fishman. |
| Is Iterum Therapeutics publicly listed? | Yes, Iterum Therapeutics is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Iterum Therapeutics? | Iterum Therapeutics trades under ITRMF ticker. |
| When did Iterum Therapeutics go public? | Iterum Therapeutics went public in 2018. |
| Who are competitors of Iterum Therapeutics? | Iterum Therapeutics main competitors are Respiratorius, PharmaLundensis, Reboost Blockchain, Aptahem. |
| What is the current market cap of Iterum Therapeutics? | Iterum Therapeutics' current market cap is $1M. |
| What is the current revenue of Iterum Therapeutics? | Iterum Therapeutics' last 12 months revenue is $3M. |
| What is the current revenue growth of Iterum Therapeutics? | Iterum Therapeutics revenue growth (NTM/LTM) is 602%. |
| What is the current EV/Revenue multiple of Iterum Therapeutics? | Current revenue multiple of Iterum Therapeutics is 6.9x. |
| Is Iterum Therapeutics profitable? | No, Iterum Therapeutics is not profitable. |
| What is the current EBITDA of Iterum Therapeutics? | Iterum Therapeutics has negative EBITDA and is not profitable. |
| What is Iterum Therapeutics' EBITDA margin? | Iterum Therapeutics' last 12 months EBITDA margin is (643%). |
| What is the current EV/EBITDA multiple of Iterum Therapeutics? | Current EBITDA multiple of Iterum Therapeutics is (1.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.